ASH 2011; new data on eltrombopag treatment of chronic immune thrombocytopenia (ITP) and hepatitis C

摘要

An update of the ongoing open-label extension study EXTEND confirms the safety and efficacy of eltrombopag, an oral, nonpeptide thrombopoetin receptor agonist, in the long-term treatment of chronic ITP patients [1]. The study comprises 301 previously treated patients who completed a prior eltrombopag trial. Roughly one-third of the participants (38%) were splenect-omised, 34% used concomitant ITP mediation at baseline, and more than half of the patients (53%) had received at least 3 prior ITP therapies.At the time of the new analysis, the median duration of exposure to the drug was 121 weeks. 215 patients (71%) had received eltrombopag for at least 12 months, 176 patients (58%) for at least 24 months. 84 patients (28%) were already treated for 3 years and more.